Hyperbaric Oxygen Therapy for Treating PTSD and Cognitive Decline with Dr. Mohammed Elamir Aviv Clinics TRANSCRIPT
Release Date: 09/26/2024
New Gut-Brain Signaling Drug Targets Prader-Willi Syndrome with Dr. Tien Lee Aardvark Therapeutics TRANSCRIPT
Empowered Patient Podcast
Dr. Tien Lee, Founder and CEO of Aardvark Therapeutics, draws a clear distinction between appetite and hunger and the implications for treating metabolic conditions and managing weight. The Aardvark lead drug candidate, an oral bitter taste receptor agonist designed to activate the gut-brain connection to turn off hunger, is showing effectiveness in treating Prader-Willi Syndrome and general obesity. There are also signs that this drug could be effective for those using GLP-1s to avoid nausea and prevent rebound weight gain experienced after discontinuing GLP-1 drugs. Tien explains,...
info_outline
New Gut-Brain Signaling Drug Targets Prader-Willi Syndrome with Dr. Tien Lee Aardvark Therapeutics
Empowered Patient Podcast
Dr. Tien Lee, Founder and CEO of Aardvark Therapeutics, draws a clear distinction between appetite and hunger and the implications for treating metabolic conditions and managing weight. The Aardvark lead drug candidate, an oral bitter taste receptor agonist designed to activate the gut-brain connection to turn off hunger, is showing effectiveness in treating Prader-Willi Syndrome and general obesity. There are also signs that this drug could be effective for those using GLP-1s to avoid nausea and prevent rebound weight gain experienced after discontinuing GLP-1 drugs. Tien explains,...
info_outline
New Hepatitis B Oral Treatment Blocks Viral Integration and Progression with Lawrence Blatt Aligos Therapeutics TRANSCRIPT
Empowered Patient Podcast
Lawrence Blatt, Chairman, President, and CEO of Aligos Therapeutics, describes the current gaps in treating the hepatitis B virus and how the disease can potentially lead to end-stage liver disease and liver cancer. Current therapies were initially developed for HIV and can suppress the virus but not eliminate or prevent the disease. The lead Aligos drug candidate blocks all steps of viral replication and prevents the virus from integrating into infected liver cells, where it can activate cancer-causing genes. Lawrence explains, "Hepatitis B virus is actually the most prevalent chronic...
info_outline
New Hepatitis B Oral Treatment Blocks Viral Integration and Progression with Lawrence Blatt Aligos Therapeutics
Empowered Patient Podcast
Lawrence Blatt, Chairman, President, and CEO of Aligos Therapeutics, describes the current gaps in treating the hepatitis B virus and how the disease can potentially lead to end-stage liver disease and liver cancer. Current therapies were initially developed for HIV and can suppress the virus but not eliminate or prevent the disease. The lead Aligos drug candidate blocks all steps of viral replication and prevents the virus from integrating into infected liver cells, where it can activate cancer-causing genes. Lawrence explains, "Hepatitis B virus is actually the most prevalent chronic...
info_outline
Reality Check from Biotech Leaders on Using AI in Drug Discovery with BioXcel Therapeutics Gain Therapeutics iBio TRANSCRIPT
Empowered Patient Podcast
This roundtable on the role of AI in the biotech sector features Frank Yocca, Senior VP and Chief Scientific Officer at BioXcel Therapeutics, Joanne Taylor, Senior VP for Research at Gain Therapeutics, and Martin Brenner, CEO and Chief Scientific Officer at iBio. The conversation covers the historical adoption of AI in biotech, its current use in drug discovery, and future possibilities. AI is not a new phenomenon in biotech and has evolved from data processing to sophisticated models that can screen vast amounts of data. There is a critical need for high-quality, structured data to...
info_outline
Reality Check from Biotech Leaders on Using AI in Drug Discovery with BioXcel Therapeutics Gain Therapeutics iBio
Empowered Patient Podcast
This roundtable on the role of AI in the biotech sector features Frank Yocca, Senior VP and Chief Scientific Officer at BioXcel Therapeutics, Joanne Taylor, Senior VP for Research at Gain Therapeutics, and Martin Brenner, CEO and Chief Scientific Officer at iBio. The conversation covers the historical adoption of AI in biotech, its current use in drug discovery, and future possibilities. AI is not a new phenomenon in biotech and has evolved from data processing to sophisticated models that can screen vast amounts of data. There is a critical need for high-quality, structured data to...
info_outline
Developing Multi-Antigen Vaccines for Immunocompromised Patients with David Dodd GeoVax TRANSCRIPT
Empowered Patient Podcast
David Dodd, CEO of GeoVax, highlights the need for next-generation vaccines, specifically multi-antigen and T cell-focused technologies, to provide better protection for immunocompromised populations. Their pipeline includes a COVID-19 vaccine candidate, an Mpox/Smallpox vaccine, and a gene therapy for solid tumors. A priority for GeoVax is to develop new manufacturing processes to significantly accelerate vaccine production, increase yield, and reduce costs. David explains, "Multi-antigen vaccines become critically important, especially for populations for whom the existing approach in...
info_outline
Developing Multi-Antigen Vaccines for Immunocompromised Patients with David Dodd GeoVax
Empowered Patient Podcast
David Dodd, CEO of GeoVax, highlights the need for next-generation vaccines, specifically multi-antigen and T cell-focused technologies, to provide better protection for immunocompromised populations. Their pipeline includes a COVID-19 vaccine candidate, an Mpox/Smallpox vaccine, and a gene therapy for solid tumors. A priority for GeoVax is to develop new manufacturing processes to significantly accelerate vaccine production, increase yield, and reduce costs. David explains, "Multi-antigen vaccines become critically important, especially for populations for whom the existing approach in...
info_outline
Virtual Support Groups Remove Barriers Encourage Sharing Honest Experiences to Fight Misinformation with Rick Davis AnCan TRANSCRIPT
Empowered Patient Podcast
Rick Davis, patient advocate and Founder of AnCan, is building and operating virtual peer-to-peer support groups to allow patients to connect with others who have direct experience with their condition. These groups can provide accurate information, foster connections among participants, and serve as a check on medical misinformation. With the growing acceptance of virtual meetings, this approach overcomes geographic, physical, and psychosocial barriers that might otherwise prevent participants from attending on-site meetings. Rick explains, "The mission is to make each person and each...
info_outline
Virtual Support Groups Remove Barriers Encourage Sharing Honest Experiences to Fight Misinformation with Rick Davis AnCan
Empowered Patient Podcast
Rick Davis, patient advocate and Founder of AnCan, is building and operating virtual peer-to-peer support groups to allow patients to connect with others who have direct experience with their condition. These groups can provide accurate information, foster connections among participants, and serve as a check on medical misinformation. With the growing acceptance of virtual meetings, this approach overcomes geographic, physical, and psychosocial barriers that might otherwise prevent participants from attending on-site meetings. Rick explains, "The mission is to make each person and each...
info_outlineDr. Mohammed Elamir, lead physician at Aviv Clinics, offers diagnostics and treatments for brain injuries such as PTSD, stroke, and traumatic brain injury and to address cognitive decline. After comprehensive physical and mental assessment, including brain scans, patients receive hyperbaric oxygen therapy and other therapies like psychotherapy and neurocognitive training. Individualized plans are designed to get to the root causes of neurological and cognitive issues and stimulate the growth of new cells and blood flow, even for patients with long-standing conditions.
Dr. Mo explains, "Our pre-assessment testing is a lot more rigorous than your kind of annual physical. We do three to five days of testing that can involve medical evaluations with the medical doctors and advanced blood work for different biomarkers for injury or inflammation. Two very specific brain scans that I think separate our assessment from most, and one is an MRI with DTI analysis. That is a microstructure analysis of the brain. So we can look at the nerve tracks running through the brain, how well-connected, and how dense they are."
"If somebody’s approved for the treatment, they would undergo up to a 12-week treatment regimen involving hyperbaric oxygen therapy. And we can go into the details of that oxygen therapy, but in addition to that, they’ll have other appointments, whether it’s PT, psychological counseling, or neurocognitive training. And by the end of the 12 weeks, they should be feeling better, but objectively, we want to see why. We repeat the entire pre-treatment assessment at the end so we can have an objective comparison."
#AvivClinics #HBOT #Hyperbaricmedicine #PTSD #Stoke #Aging
